Icon Plc (NASDAQ:ICLR) has earned a consensus rating of “Buy” from the twelve brokerages that are currently covering the firm, MarketBeat reports. Three investment analysts have rated the stock with a hold recommendation, eight have assigned a buy recommendation and one has issued a strong buy recommendation on the company. The average 1-year price target among brokerages that have updated their coverage on the stock in the last year is $108.00.

A number of research analysts have commented on the company. KeyCorp restated an “overweight” rating on shares of Icon Plc in a research note on Monday, July 31st. SunTrust Banks, Inc. upgraded Icon Plc from a “hold” rating to a “buy” rating and boosted their price objective for the stock from $93.00 to $126.00 in a research note on Monday, July 31st. Mizuho boosted their price objective on Icon Plc from $104.00 to $108.00 and gave the stock a “neutral” rating in a research note on Thursday, July 27th. Jefferies Group LLC restated a “buy” rating on shares of Icon Plc in a research note on Sunday, July 30th. Finally, ValuEngine cut Icon Plc from a “buy” rating to a “hold” rating in a research note on Wednesday, May 31st.

Several hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Bancorpsouth Inc. boosted its position in Icon Plc by 8.8% in the second quarter. Bancorpsouth Inc. now owns 7,486 shares of the medical research company’s stock valued at $732,000 after buying an additional 606 shares during the period. OxFORD Asset Management LLP boosted its position in Icon Plc by 69.7% in the second quarter. OxFORD Asset Management LLP now owns 65,281 shares of the medical research company’s stock valued at $6,384,000 after buying an additional 26,817 shares during the period. Blue Jay Capital Management LLC acquired a new position in Icon Plc during the second quarter valued at approximately $6,194,000. Renaissance Technologies LLC boosted its position in Icon Plc by 20.6% in the second quarter. Renaissance Technologies LLC now owns 1,153,160 shares of the medical research company’s stock valued at $112,768,000 after buying an additional 197,300 shares during the period. Finally, Parametric Portfolio Associates LLC boosted its position in Icon Plc by 9.7% in the second quarter. Parametric Portfolio Associates LLC now owns 154,435 shares of the medical research company’s stock valued at $15,102,000 after buying an additional 13,634 shares during the period. Institutional investors and hedge funds own 92.55% of the company’s stock.

Shares of Icon Plc (NASDAQ ICLR) traded down 0.61% during midday trading on Friday, reaching $101.40. The company’s stock had a trading volume of 233,718 shares. Icon Plc has a 52 week low of $73.76 and a 52 week high of $109.32. The firm has a market capitalization of $5.48 billion, a price-to-earnings ratio of 20.57 and a beta of 0.60. The firm’s 50 day moving average is $100.50 and its 200 day moving average is $89.05.

Icon Plc (NASDAQ:ICLR) last issued its earnings results on Thursday, July 27th. The medical research company reported $1.31 earnings per share for the quarter, beating the Zacks’ consensus estimate of $1.30 by $0.01. Icon Plc had a return on equity of 28.72% and a net margin of 15.97%. The firm had revenue of $431 million for the quarter, compared to analysts’ expectations of $430.68 million. During the same quarter last year, the firm earned $1.14 earnings per share. The firm’s revenue for the quarter was up 5.0% compared to the same quarter last year. Equities analysts forecast that Icon Plc will post $5.32 EPS for the current fiscal year.

WARNING: This report was first reported by American Banking News and is owned by of American Banking News. If you are accessing this report on another website, it was stolen and republished in violation of United States & international trademark and copyright legislation. The legal version of this report can be viewed at https://www.americanbankingnews.com/2017/08/11/icon-plc-nasdaqiclr-receives-average-recommendation-of-buy-from-brokerages.html.

Icon Plc Company Profile

ICON public limited company is a contract research organization (CRO), which is engaged in providing outsourced development services to the pharmaceutical, biotechnology and medical device industries. The Company is engaged in the strategic development, management and analysis of programs that support the various stages of the clinical development process, from compound selection to Phase I-IV clinical studies.

Analyst Recommendations for Icon Plc (NASDAQ:ICLR)

Receive News & Ratings for Icon Plc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Icon Plc and related companies with MarketBeat.com's FREE daily email newsletter.